Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 5Phase 1 5Phase 2/3 3Phase NA 2Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 8Pancreatic Neoplasms 7Breast Neoplasms 7Colorectal Neoplasms 6Stomach Neoplasms 5Neoplasms 5Sarcoma 3Precision Cell Immunotherapy 3Ovarian Neoplasms 3Neoplasm Metastasis 3Mesothelioma, Malignant 3Lung Neoplasms 3Leukemia, Myeloid, Acute 3Hodgkin Disease 3Glioblastoma 3Esophageal Neoplasms 3Wilms Tumor 2Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Mesothelioma 2Melanoma 2Lymphoma 2Head and Neck Neoplasms 2Fallopian Tube Neoplasms 2Esophageal Squamous Cell Carcinoma 2Colonic Neoplasms 2Cholangiocarcinoma 2Carcinoma, Ovarian Epithelial 2Virus Diseases 1

Interventions

Cyclophosphamide 42Cytarabine 25fludarabine phosphate 24Dexamethasone 23Methotrexate 22fludarabine 21Peripheral Blood Stem Cell Transplantation 21Vincristine 16Filgrastim 16venetoclax 14Etoposide 13Rituximab 12Mycophenolic Acid 12Whole-Body Irradiation 11Cyclosporine 10Clofarabine 10Calcium Dobesilate 10blinatumomab 9Tacrolimus 9pegaspargase 8Busulfan 8Bortezomib 8Alemtuzumab 8Mitoxantrone 7Melphalan 7Leucovorin 7Immunotherapy, Adoptive 7nilotinib 6Mesna 6Mercaptopurine 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Precursor Cell Lymphoblastic Leukemia-Lymphoma × Drug Therapy × Clear all
NCT04764513 2022-03-28

Safety and Efficiency of γδ T Cell Against Hematological Malignancies After Allo-HSCT

Chinese PLA General Hospital

Phase 1/2 Unknown
20 enrolled
LymphoidMyeloidOther hematologic neoplasm

Lymphoma, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡